The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Analysis of the tumor microenvironment in ineffective patients of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma.
 
Kazufumi Kobayashi
No Relationships to Disclose
 
Sadahisa Ogasawara
Honoraria - Bayer; Chugai Pharma; Eisai; Lilly; Merck
Consulting or Advisory Role - AstraZeneca; Bayer; Chugai Pharma; Lilly; Merck
Research Funding - AstraZeneca; Bayer; Chugai Pharma; Eisai; Lilly
 
Takamasa Ishino
No Relationships to Disclose
 
Hidemi Unozawa
No Relationships to Disclose
 
Miyuki Nakagawa
No Relationships to Disclose
 
Kisako Fujiwara
No Relationships to Disclose
 
Takafumi Sakuma
No Relationships to Disclose
 
Naoto Fujita
No Relationships to Disclose
 
Hiroaki Kanzaki
No Relationships to Disclose
 
Keisuke Koroki
No Relationships to Disclose
 
Masato Nakamura
No Relationships to Disclose
 
Soichiro Kiyono
No Relationships to Disclose
 
Naoya Kanogawa
No Relationships to Disclose
 
Takayuki Kondo
No Relationships to Disclose
 
Tomoko Saito
No Relationships to Disclose
 
Ryo Nakagawa
No Relationships to Disclose
 
Shingo Nakamoto
No Relationships to Disclose
 
Ryosuke Muroyama
No Relationships to Disclose
 
Tetsuhiro Chiba
No Relationships to Disclose
 
Naoya Kato
Speakers' Bureau - Abbott; Abbvie; Aska Pharmaceutical Co., Ltd.; Astellas Pharma; AstraZeneca Japan; Bayer Yakuhin; Bristol-Myers Squibb Company; Chugai Pharma; Covidien; Daiichi Sankyo Co.,Ltd.; EA Pharma; Eisai; Fujifilm; Gilead Sciences; Kowa; Lilly Japan; Mitsubishi Tanabe Pharma; Miyarisan pharmaceutical; Mochida Pharmaceutical Co. Ltd.; MSD K.K; Mylan; Nichi-iko; Nippon Kayaku; Nobelpharma; Olympus; Ono Pharmaceutical; Otsuka; Shionogi; Sumitomo Dainippon Pharma Co., Ltd.; Takeda; Tsumura & Co.; Zeria Pharmaceutical
Research Funding - Abbvie (Inst); Asahi Kasei (Inst); Asahi Kasei (Inst); Aska Pharmaceutical Co.,Ltd. (Inst); Astellas Pharma (Inst); Boston Scientific (Inst); Chugai Pharma (Inst); Covidien (Inst); CYTLIMIC (Inst); Daiichi Sankyo co.,Ltd. (Inst); EA Pharma (Inst); Eisai (Inst); Gilead Sciences (Inst); JIMRO (Inst); Kowa (Inst); Medicos Hirata (Inst); Mitsubishi Tanabe Pharma (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); MSD K.K. (Inst); Nippon Kayaku (Inst); Otsuka (Inst); Shionogi (Inst); Sumitomo Dainippon Pharma Co.,Ltd. (Inst); Takeda (Inst); Tsumura & Co. (Inst)